Search results
Results from the WOW.Com Content Network
Investors can now consider renewable products company Amyris (NASDAQ:AMRS) as a "marijuana stock." The Emeryville, California-based firm signed a deal to license cannabinoid products. This sent ...
Shares of bioscience firm Amyris (AMRS) skyrocketed more than 70% on Tuesday after the company announced a collaboration deal focused on developing, licensing, and commercializing cannabinoid ...
Amyris, Inc. is a synthetic biotechnology and renewable chemical company headquartered in Emeryville, California. Amyris serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.
Amyris, Inc. (AMRS) closed the most recent trading day at $4.48, moving +0.45% from the previous trading session.
The stock of Amyris (NAS:AMRS, 30-year Financials) is estimated to be significantly overvalued, according to GuruFocus Value calculation.
For premium support please call: 800-290-4726 more ways to reach us
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F ...
Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings. In a ...